Ophthalmology and Therapy is a premier open-access journal published by Springer International Publishing AG, dedicated to advancing the field of ophthalmology through innovative research and clinical studies. With an ISSN of 2193-8245 and an E-ISSN of 2193-6528, this journal serves as a vital resource for researchers, healthcare professionals, and students interested in the latest developments in eye care and vision science. The journal has achieved a remarkable impact factor and has been recognized as a Q1 journal in Ophthalmology, reflecting its contributions to the discipline and its high-quality publications. Operating from the United Kingdom, Ophthalmology and Therapy is an open-access platform that has been available since 2012, ensuring that critical research is accessible to a global audience. Its commitment to fostering collaboration and knowledge sharing is exemplified by its ranking of #39 out of 137 in the Scopus category for Medicine – Ophthalmology, placing it in the 71st percentile of its peers. Together, these attributes highlight the journal's importance as a key forum for the dissemination of cutting-edge research, making it an essential addition to the libraries of institutions and professionals engaged in ophthalmic care.

International Ophthalmology is a prestigious journal published by Springer, dedicated to advancing the field of ophthalmology through the dissemination of high-quality research and clinical studies. With an ISSN of 0165-5701 and an E-ISSN of 1573-2630, this journal has been a vital resource since its inception in 1978, serving the global community of ophthalmologists, researchers, and healthcare professionals. The journal holds a significant Q2 ranking in the category of ophthalmology and has achieved a commendable position as #56 in Scopus's rankings, placing it within the top tier of its field. Although it does not offer open-access options, articles published in International Ophthalmology are widely cited and respected, playing a crucial role in the ongoing dialogue regarding contemporary ophthalmic practices and innovations. With a broad scope covering all aspects of eye care, this journal is essential for those aiming to keep abreast of the latest developments and research findings that shape the future of vision science and clinical practice.

ARQUIVOS BRASILEIROS DE OFTALMOLOGIA is a prominent peer-reviewed journal dedicated to the field of ophthalmology, published by CONSEL BRASIL OFTALMOLOGIA since its inception in 1945. With its commitment to disseminating high-quality research, the journal has transitioned to an Open Access model since 2001, ensuring that vital findings in ophthalmology are freely available to researchers, clinicians, and students alike. Located in São Paulo, Brazil, this esteemed publication occupies a significant position in the medical field, currently holding a Q3 ranking in both the miscellaneous medicine and ophthalmology categories. Although it maintains a legacy of fluctuating impact, recognized for its contribution to the academic community, ARQUIVOS BRASILEIROS DE OFTALMOLOGIA continues to attract a diverse international readership, making it a valuable resource for advancements in eye health, surgical techniques, and ocular research.

JAMA Ophthalmology, the premier journal in the field of ophthalmology, is published by the esteemed American Medical Association. Renowned for its rigorous peer-review process and commitment to advancing eye health research, JAMA Ophthalmology holds a prestigious position in the scientific community, boasting an impressive impact factor and ranking as Q1 in the category of Ophthalmology. With a Scopus rank of #3 out of 137 in its field and a remarkable 98th percentile, the journal serves as an invaluable resource for researchers, healthcare professionals, and students dedicated to the ophthalmic sciences. Readers can explore a wealth of cutting-edge findings, clinical studies, and review articles that not only contribute to the sustainable advancement of ophthalmic knowledge but also foster innovative approaches in patient care. As we converge into 2024, the journal continues to embrace open access principles, ensuring that groundbreaking research is readily available to a global audience, enhancing collaborative efforts and furthering the development of the ophthalmology discipline.

BMC Ophthalmology is a premier open access journal dedicated to advancing the field of ophthalmology through the publication of high-quality, peer-reviewed research. Published by BMC in the United Kingdom, this journal has been a vital resource since its inception in 2001 and continuously contributes to the global dialogue in vision science. With an impact factor reflecting its growing influence, BMC Ophthalmology is ranked among the top quartiles (Q2) in both general medicine and ophthalmology, emphasizing its significance in medical research. The journal encourages submissions that explore innovative diagnostics, treatment approaches, and understandings of various ocular diseases, thereby appealing to researchers, clinicians, and students alike. As an open access platform, it ensures that cutting-edge research is not only published but also readily accessible to a worldwide audience, promoting further study and collaboration in this essential area of medicine.

Journal of VitreoRetinal Diseases is a leading publication in the field of ophthalmology, specifically focusing on the complex landscape of vitreo-retinal conditions. Released by SAGE Publications Inc, this journal plays a crucial role in advancing the understanding and treatment of retinal diseases through high-quality, peer-reviewed research. With an ISSN of 2474-1264 and an E-ISSN of 2474-1272, the journal has gained recognition since its inception in 2017, currently ranking in the Q3 category of ophthalmology based on its Scopus metrics. Positioned within the 31st percentile among its peers, the journal provides a platform for the dissemination of innovative findings and clinical practices. Although it operates under a traditional access model, the significance of its contributions is profound, making it an essential resource for researchers, healthcare professionals, and students dedicated to improving patient outcomes in retinal health.

Prostate Cancer is a leading peer-reviewed Open Access journal published by HINDAWI LTD, dedicated to advancing the field of urology and oncology through high-quality research and innovative studies. Established in 2011, this journal serves as a vital platform for disseminating findings related to prostate cancer diagnostics, treatment strategies, and patient care, striving to collaborate and connect researchers from around the globe. With an impact factor reflective of its critical input in the scientific community, the journal showcases compelling manuscripts, reviews, and case reports that are accessible to a wide audience given its open access policy. Located in London, England, Prostate Cancer has made significant strides in its category quartiles, achieving Q4 in Cancer Research and Q3 in both Oncology and Urology as of 2023, reflecting its growing relevance and readership. With Scopus rankings indicating its position within the broader medical fields, the journal is a valuable resource for researchers, professionals, and students alike, contributing to the collective effort to improve outcomes in prostate cancer research and treatment.

Urogynecology, published by Lippincott Williams & Wilkins, is a distinguished journal that serves as an essential platform for researchers, clinicians, and students in the fields of obstetrics, gynecology, surgery, and urology. With an impact factor that places it in the Q2 category in various specialties, the journal emphasizes high-quality, peer-reviewed research that contributes to advancements in women's health and pelvic floor disorders. As an Open Access journal, it is committed to enhancing the accessibility of its content, allowing for broader dissemination of knowledge and fostering collaborative efforts in the medical community. Located in India and addressing a global audience, Urogynecology has quickly established its reputation since its inception in 2022, continuing through its converged years until 2024. It is ranked favorably in Scopus across several medical categories, providing a vital resource for cutting-edge research and clinical practice insights. This journal aims to bridge gaps in knowledge and practice, making it an invaluable asset for anyone dedicated to improving outcomes in urogynecology.

Klinische Monatshefte für Augenheilkunde is a distinguished peer-reviewed journal published by Georg Thieme Verlag KG, dedicated to advancing knowledge in the field of ophthalmology and general medicine. With an ISSN of 0023-2165 and an E-ISSN of 1439-3999, this journal has been a reputable platform for researchers and clinicians since its inception in 1963, continuing its impactful contributions through to 2024. Recognized in the Q3 quartile for both Medicine (miscellaneous) and Ophthalmology, this journal serves as a vital resource for those involved in ocular health, offering insights into clinical practices, recent advancements, and essential research findings. Despite its traditional publishing model, the journal retains a significant role in the academic community, as evidenced by its current Scopus ranking of #90/137 in the field of Ophthalmology. It is an essential read for professionals and students aiming to stay at the forefront of ophthalmic research and clinical innovations.

Urologic Oncology - Seminars and Original Investigations is a premier journal published by Elsevier Science Inc, dedicated to advancing the field of urologic oncology through high-quality, peer-reviewed research and insightful scholarly discussions. With an ISSN of 1078-1439 and an E-ISSN of 1873-2496, this journal has established itself as a vital resource for professionals, researchers, and students alike since its inception in 1995. Currently holding a Q2 ranking in Oncology and a prestigious Q1 in Urology for 2023, it ranks 28th out of 120 in Urology and 177th out of 404 in Oncology within Scopus, underscoring its relevance and impact in these critical fields. While the journal operates under a subscription model, it continues to deliver compelling and transformative research aimed at enhancing patient outcomes in urologic oncology. With a focus on innovative therapies, diagnostic advancements, and clinical trials, the journal contributes significantly to ongoing dialogue and development in urologic health care.